tobramycin has been researched along with Drug-Induced Cochlear Toxicity in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Čusak, A; Durán-Alonso, MB; Fernández-Martínez, M; Fujs, Š; García-Mateo, N; Ishikawa, M; Knipper, M; Kosec, G; López-Hernández, I; Löwenheim, H; Martínez-Martínez, L; Müller, M; Petković, H; Rüttiger, L; Schimmang, T; Singer, W | 1 |
| Baladi, B; Calmels, MN; Concordet, D; Gallois, Y; Gandia, P; Madaule, J; Mittaine, M; Murris, M; Valenzuela, F | 1 |
| Burt, RA; Lockhart, PJ; Ogier, JM | 1 |
| Gu, R; Homan, J; Kil, J; Longenecker, RJ | 1 |
| Garinis, A; Gleser, M; Johns, A; Larsen, E; Vachhani, J | 1 |
| Dorgan, D; Fifer, RC; Flume, PA; Harruff, EE; Jain, R; Kil, J; Kim, YJM; Ortiz, MGT; Poth, EA; Shoup, AG | 1 |
| Blankenship, CA; Dong, M; Hunter, LL; McPhail, G; Rodriguez, AV; Vinks, AA | 1 |
7 other study(ies) available for tobramycin and Drug-Induced Cochlear Toxicity
| Article | Year |
|---|---|
Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cell Line; Drug Resistance, Bacterial; Gentamicins; Guinea Pigs; Hair Cells, Auditory, Inner; Hearing Loss; Humans; Nebramycin; Neomycin; Ototoxicity; Protein Synthesis Inhibitors; Round Window, Ear | 2019 |
Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Cystic Fibrosis; Hearing Loss; Humans; Ototoxicity; Retrospective Studies; Tobramycin | 2023 |
Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Drug Administration Schedule; Hearing; Hearing Loss; Injections, Intravenous; Kidney; Kidney Diseases; Mice, Inbred C57BL; Ototoxicity; Species Specificity; Time Factors; Tobramycin | 2020 |
Ebselen attenuates tobramycin-induced ototoxicity in mice.
Topics: Animals; Evoked Potentials, Auditory, Brain Stem; Hair Cells, Auditory, Outer; Hearing Loss; Isoindoles; Mice; Organoselenium Compounds; Ototoxicity; Tobramycin | 2021 |
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
Topics: Administration, Intravenous; Adolescent; Adult; Aminoglycosides; Audiometry, Pure-Tone; Cystic Fibrosis; Female; Hearing Loss; Humans; Male; Middle Aged; Ototoxicity; Prospective Studies; Tobramycin | 2021 |
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Topics: Administration, Intravenous; Adolescent; Adult; Aminoglycosides; Audiometry, Pure-Tone; Cystic Fibrosis; Female; Hearing Loss; Humans; Male; Middle Aged; Ototoxicity; Respiratory Tract Infections; Symptom Flare Up; Tobramycin | 2021 |
Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bayes Theorem; Cystic Fibrosis; Humans; Ototoxicity; Tobramycin | 2021 |